Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal

In a week without novel agent approvals, US FDA action on new products based on already approved molecules took center stage.

Novartis AG’s kinase inhibitor alpelisib, which the company markets as Piqray in breast cancer, received approval under a separate NDA as Vijoice for a group of orphan overgrowth conditions....